CD37

CD37 Overview

English NameLeukocyte antigen CD37Approved Drugs0
Drugs in Clinical Trials7Target SynonymCD37,Tetraspanin-26,CD37 Molecule,CD37 Antigen,Tspan-26,TSPAN26,Cell Differentiation Antigen 37,Leukocyte Surface Antigen CD37,Leukocyte Antigen CD37,GP52-40
Highest Development StagePhase 2 Clinical
English NameLeukocyte antigen CD37
Target SynonymCD37,Tetraspanin-26,CD37 Molecule,CD37 Antigen,Tspan-26,TSPAN26,Cell Differentiation Antigen 37,Leukocyte Surface Antigen CD37,Leukocyte Antigen CD37,GP52-40
Approved Drugs0
Drugs in Clinical Trials7
Highest Development StagePhase 2 Clinical

CD37 Product List

  • Product Category

    Protein (5)

  • Product Status

    Launched (6)

  • Species

    Human (5)

  • Tag

    Fc Tag (2)His Tag (1)- (3)

  • Conjugate

    Unconjugated (4)FITC Labeled (1)

CD37 Background

Leukocyte antigen CD37 (CD37) is also known as Tetraspanin-26 (Tspan-26) and TSPAN26,which is a member of the transmembrane 4 superfamily or tetraspanin family. Most of these members are cell-surface proteins that are characterized by the presence of four hydrophobic domains. The proteins encoded by CD37 gene mediate signal transduction events that play a role in the regulation of cell development, activation, growth and motility. CD37 is a cell surface glycoprotein that is known to complex with integrins and other transmembrane 4 superfamily proteins. CD37 may play a role in T-cell-B-cell interactions.

CD37 Synonyms

CD37,Tspan-26,TSPAN26

Project Cooperation

Project NameDrug TypeTherapeutic AreaIndicationStageRights Area
CD37+CD22 CAR-TCell therapyOncology/CancerAMLPCCGlobal

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
Lutetium (177lu) lilotomab satetraxetan177Lu-DOTA-HH1Phase 2 ClinicalNordic NanovectorLymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Non-Hodgkin
Details
Naratuximab emtansineIMGN-529; K7153A-SMCC-DM1Phase 2 ClinicalImmunogen IncLymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell
Details
AGS-67EAGS-67EPhase 1 ClinicalAgensys IncLeukemia, Hairy Cell; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell
Details
CAR-37 T cell therapy (Massachusetts General Hospital)Phase 1 ClinicalMassachusetts General HospitalLymphoma, B-Cell; Leukemia; Hematologic Neoplasms; Lymphoma, Non-Hodgkin; Lymphoma; Lymphoma, T-Cell
Details
CAR-37 T cells(The General Hospital)Phase 1 ClinicalThe General Hospital Corporation D/B/A Massachusetts General HospitalHematologic Neoplasms; Leukemia; Lymphoma, B-Cell; Lymphoma, T-Cell; Lymphoma, Non-Hodgkin; Lymphoma
Details
QLP-31907QLP-31907; QLP31907; PSB-202Phase 1 ClinicalQilu Pharmaceutical Co LtdLymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Waldenstrom Macroglobulinemia; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell
Details
anti-CD19 + anti-CD37 bispecific CAR T-cell therapy (Forevertek Biotechnology/Huazhong University of Science and Technology)ClinicalHuazhong University Of Science And TechnologyLymphoma, Non-Hodgkin
Details
  • Overview
  • Product List
  • Clinical Drug Information